Health
Johnson & Johnson’s Coronavirus Vaccine Candidate Efficacious in Pre-Clinical Studies; Human Testing Has Begun – The Motley Fool
The company aims to start a phase 3 clinical trial for Ad26.COV2-S in September.
Johnson & Johnson(NYSE:JNJ) has gained some ground in the coronavirus vaccine race. On Thursday, the pharmaceutical and consumer goods company announced that in pre-clinical studies, its Ad26.COV2-S vaccine candidate had demonstrated effectiveness in protecting on non-human primates from infection with SARS-CoV-2.
In contrast to other coronavirus vaccine candidates — such as the one many observers view as the most promising, Moderna’s mRNA-1273 — Johnson & Johnson’s produced its respo…
-
General13 hours agoBunbury man Stanley J Clemons sentenced for shooting neighbour’s dog
-
Business16 hours agoThese 4 ASX mining stocks are rocketing as the rare earths boom intensifies
-
General23 hours agoAustralia solved civilisation’s problems
-
Business21 hours agoThis artificial intelligence (AI) stock will be the Nvidia of quantum computing by 2035